BiotechTube

Isavuconazonium sulfate + Voriconazole + Posaconazole

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Invasive Fungal Infection

Conditions

Invasive Fungal Infection

Trial Timeline

Mar 16, 2017 → Apr 24, 2020

NCT ID
NCT03066011

About Isavuconazonium sulfate + Voriconazole + Posaconazole

Isavuconazonium sulfate + Voriconazole + Posaconazole is a pre-clinical stage product being developed by Astellas Pharma for Invasive Fungal Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03066011. Target conditions include Invasive Fungal Infection.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT03066011Pre-clinicalCompleted

Competing Products

20 competing products in Invasive Fungal Infection

See all competitors
ProductCompanyStageHype Score
BSG005Alkem LaboratoriesPhase 1/2
41
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
51
Trastuzumab deruxtecan + DurvalumabDaiichi SankyoPhase 2
52
Isavuconazole + Caspofungin + VoriconazoleAstellas PharmaPhase 3
77
Micafungin + fluconazoleAstellas PharmaPhase 3
77
MicafunginAstellas PharmaPre-clinical
23
Micafungin (Mycamine)Astellas PharmaPhase 1
33
Pudexacianinium chlorideAstellas PharmaPhase 2
52
Enfortumab vedotin + PembrolizumabAstellas PharmaPhase 2
52
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
52
Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
77
Isavuconazonium sulfate + Isavuconazonium sulfateAstellas PharmaPhase 2
52
Micafungin + Systemic antifungal therapyAstellas PharmaPhase 2
52
MicafunginAstellas PharmaPre-clinical
23
Micafungin + PlaceboAstellas PharmaPhase 3
77
MicafunginAstellas PharmaApproved
85
Olorofim + AmBisome®ShionogiPhase 3
77
Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel + Epirubicin or doxorubicin, cyclophosphamide, paclitaxelJiangsu Hengrui MedicinePhase 3
77
SHR-A1811 + Trastuzumab EmtansineJiangsu Hengrui MedicinePhase 3
77
Herombopag tablets + Herombopag placebo tabletsJiangsu Hengrui MedicinePhase 3
77

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85